Analytical and radioanalytical quality control of purity and stability of radiopharmaceutical compound [ 186g Re]Re-HEDP for bone metastases pain palliation

The nuclear properties of 186g Re make it a useful agent for radionuclide therapy and imaging. The coordination compound ( 186g Re)Re-HEDP has proved to be a successful bone seeking agent for palliation of metastatic bone pain. Chemical, radiochemical and radionuclidic purity of commercial radiopharmaceutical ( 186g Re)Re-HEDP have been checked by means by �- and �-spectrometries, INAA and paper radio- chromatography. The results indicate a good radionuclidic purity, with levels of contamination from the short-lived 188 Re well below the required specifications. After injection of the radiopharmaceutical, the radiochemical measurements conducted in vivo, on biological matrices, blood, plasma and urine, have shown that, entering the systemic circulation, 186g Re dissociates from the bis-phosphonate complex as hydrosoluble ( 186g Re)ReO4 - , and the two chemical species follow different biokinetics.